SGLT2抑制剂引起2型糖尿病患者上呼吸道感染的网状Meta分析#br#

摘要/Abstract

摘要： 目的：采用网状Meta分析的方法对不同SGLT2（钠葡萄糖共转运蛋白2）抑制剂引起2型糖尿病患者上呼吸道感染风险的相关性进行系统评价。方法：检索相关中英文数据库，获取不同SGLT2抑制剂治疗2型糖尿病患者的随机对照试验，检索时间从建库至2023年2月。按照纳入和排除标准筛选文献、提取数据并对纳入的研究进行方法学质量评价，使用Stata 15.1软件进行网状 Meta 分析。结果：最终纳入12篇文献，共5 615例患者。网状Meta分析结果显示，卡格列净300 mg与恩格列净10 mg（RR=1.74，95%CI=1.05，5.75）及安慰剂（RR=1.10，95% CI=1.06，4.83）相比，发生上呼吸道感染的风险增高，其他不同剂量的SGLT2 抑制剂之间相比较差异无统计学意义；网状 Meta 分析排序结果显示，SGLT2抑制剂治疗2型糖尿病时不容易引起上呼吸道感染事件发生的排序结果为卡格列净50 mg>恩格列净10 mg>达格列净1 mg>埃格列净1 mg>埃格列净5 mg>达格列净2.5 mg>达格列净5 mg>卡格列净100 mg>埃格列净10 mg>埃格列净25 mg>安慰剂>恩格列净25 mg>达格列净10 mg>卡格列净200 mg>卡格列净300 mg。结论：SGLT2抑制剂治疗2型糖尿病时卡格列净50 mg的上呼吸感染发生率最低，卡格列净300 mg发生率最高。

关键词: 钠葡萄糖共转运蛋白2抑制剂, 上呼吸道感染, 2型糖尿病, 网状Meta分析

Abstract: Objective：To systematically evaluate the correlation between the risk of upper respiratory tract infection caused by different SGLT2 (sodium glucose cotransporter2) inhibitors in patients with type 2 diabetes by using a mesh metaanalysis method. Methods：The relevant Chinese and English databases were searched to obtain the randomized controlled trials of different SGLT2 inhibitors in the treatment of type 2 diabetes patients. The search time was from the establishment of the database to February 2023. According to the inclusion and exclusion criteria， literature was screened， data was extracted， and methodological quality evaluation was conducted on the included studies. A mesh metaanalysis was conducted using Stata 15.1 software. Results：12 articles were ultimately included， with a total of 5615 patients. The results of the mesh metaanalysis showed that compared with Engliflozin 10 mg (RR=1.74， 95% CI=1.05， 5.75) and placebo (RR=1.10， 95% CI=1.06， 4.83)， Cargliflozin 300mg had an increased risk of upper respiratory tract infection. There was no statistically significant difference between other different doses of SGLT2 inhibitors； The sorting result of network metaanalysis showed that it was not easy to cause upper respiratory tract infection events when SGLT2 inhibitors were used to treat type 2 diabetes. The sorting result was cagelin 50 mg>enggligin 10 mg>daggligin 1 mg>eggligin 1 mg>eggligin 5 mg>daggligin 2.5 mg>daggligin 5 mg>caggligin 100 mg>eggligin 10 mg>eggligin 25 mg>placebo>enggligin 25 mg>daggligin 10 mg>caggligin 200 mg>caggligin 300 mg. Conclusion： When SGLT2 inhibitor is used to treat type 2 diabetes， the incidence of respiratory infection is the lowest when 50 mg of kagliflozin is used， and the highest when 300 mg of kagliflozin is used.

Key words: Sodium glucose co transporter2 inhibitor, Upper respiratory tract infection, Type 2 diabetes, Mesh Meta analysis

中图分类号:

R587
R977.15

令娟, 谢卓霖, 王燕, 张定华, 马冬梅, 罗向霞. SGLT2抑制剂引起2型糖尿病患者上呼吸道感染的网状Meta分析#br#[J]. 中国药物评价, 2023, 40(6): 530-536.

LING Juan, XIE Zhuo-lin, WANG Yan, ZHANG Ding-hua, MA Dong-mei, LUO Xiang-xia. Network Meta Analysis of Upper Respiratory Tract Infection in Type 2 Diabetes Patients Induced by SGLT2 Inhibitors#br#[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(6): 530-536.

参考文献

[1] Sun H， Saeedi P， Karuranga S， et al. IDF Diabetes Atlas： Global， regional and countrylevel diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Research and Clinical Practice， 2022， 183：109119.
[2] Islam N， Chivese T， Alam MF. Utilisation of healthcare services for respiratory tract infections in patients with and without diabetes in Qatar： a crosssectional study[J]. BMJ Open，2020，10(12)：e041761.
[3] Handelsman Y. Rationale for the Early Use of SodiumGlucose Cotransporter2 Inhibitors in Patients with Type 2 Diabetes[J]. AdvTher， 2019，36(10)：25672586.
[4] 徐爱花，黄建胜，何银辉，等. 达格列净片治疗2型糖尿病血糖控制不佳患者的疗效与低血糖风险观察[J]. 中华全科医学， 2020， 18(9)：15001503， 1526.
[5] 陈利敏，张立，刘俊伟. 恩格列净联合二甲双胍治疗2型糖尿病的效果及对低血糖发生率的影响[J]. 中国实用医刊， 2022， 49(13)：102105.
[6] 郭秀梅，季德斌. 恩格列净联合二甲双胍对2型糖尿病患者血糖水平及低血糖风险的影响[J]. 吉林医学， 2021， 42(11)：25772579.
[7] AlSayyar A， Hulme KD， Thibaut R， et al. Respiratory Tract Infections in DiabetesLessons From Tuberculosis and Influenza to Guide Understanding of COVID19 Severity[J]. Front Endocrinol (Lausanne)，2022，13：919223.
[8] Higgins J， Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. 0 [updated March 2011]. John Wiley & Sons Ltd and The Cochrane Collaboration， Chichester， 2011.
[9] Hutton B， Salanti G， Caldwell DM， et al. The PRISMA extension statement for reporting of systematic reviews incorporating network metaanalyses of health care interventions： checklist and explanations[J]. Annals of Internal Medicine， 2015， 162(11)：777784.
[10] Salanti G， Ades AE， Ioannidis JP. Graphical methods and numeri cal summaries for presenting results from multipletreatment metaan alysis： an overview and tutorial[J]. J ClinEpidemiol， 2011， 64(2)：163171.
[11] Bailey CJ， Gross JL， Pieters A， et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin： a randomised， doubleblind， placebocontrolled trial[J]. Lancet (london， england)，2010， 375(9733)：22232233.
[12] Strojek K， Yoon KH， Hruba V， et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride： a randomized， 24week， doubleblind， placebocontrolled trial[J]. Diabetes ObesMetab， 2011， 13(10)：928938.
[13] Rosenstock J， Jelaska A， Frappin G， et al. Improved glucose control with weight loss， lower insulin doses， and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes[J]. Diabetes Care， 2014， 37(7)：18151823.
[14] Strojek K， Yoon KH， Hruba V， et al. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks： a randomized， doubleblind， parallelgroup， placebocontrolled trial[J]. Diabetes Ther， 2014， 5(1)：267283.
[15] Wilding JP， Woo V， Rohwedder K， et al.Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin： efficacy and safety over 2 years[J]. Diabetes， obesity & metabolism， 2014， 16(2)：124136.
[16] Amin NB， Wang X， Jain SM， et al. Doseranging efficacy and safety study of ertugliflozin， a sodiumglucose cotransporter 2 inhibitor， in patients with type 2 diabetes on a background of metformin[J]. Diabetes， obesity & metabolism， 2015， 17(6)：591598.
[17] Bailey CJ， Morales Villegas EC， Woo V， et al. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes： a randomized doubleblind placebocontrolled 102week trial[J]. Diabetic medicine，2015， 32(4)：531541.
[18] Mathieu C， Rudofsky G， Phillip M，et al. Longterm efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT2 study)：52week results from a randomized controlled trial[J]. Diabetes， obesity & metabolism， 2020，22(9)：15161526.
[19] Rosenstock J， Zambrowicz B， Lapuerta P， et al. Impact of LX4211， a dual inhibitor of sodium glucose transporter 1 and 2 on cardiovascular risk factors in type 2 diabetes[J]. Circulation， 2012， 126(23)：2790.
[20] Inagaki， Kondo K， Yoshinari T， et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes： a randomized， doubleblind， placebocontrolled， 12week study[J]. Diabetes ObesMetab， 2013， 15(12)：11361145.
[21] Wilding JPH， Charpentier G， Hollander P， et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea： a randomisedtrial[J]. Int J ClinPract， 2013， 67(12)：12671282.
[22] Kaku K， Inoue S， Matsuoka O， et al.Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control： a phase Ⅱ multicentre， randomized， doubleblind， placebocontrolled trial[J]. Diabetes， obesity & metabolism，2013， 15(5)：432440.
[23] 丁云川．SGLT2 抑制剂治疗2型糖尿病的研究进展 [J]. 中国城乡企业卫生，2021，36（8）5557.
[24] 张雅静.钠葡萄糖协同转运蛋白 2 抑制剂在 2 型糖尿病治疗中的研究进展 [J]. 实用临床医学（江西）， 2021，22（6）：97101.